On May 12, 2026, the Trump Administration announced that FDA Commissioner Martin Makary would be resigning from his role after 13 months leading the agency. In a social media post, President Donald Trump confirmed that Kyle Diamantas, who previously worked as the top food official at FDA, will lead FDA in an acting capacity.

In recent months, Acting Commissioner Diamantas had garnered support from multiple corners of the Trump Administration and HHS Secretary Kennedy’s Make America Healthy Again (MAHA) movement to serve as acting commissioner. Acting Commissioner Diamantas joined FDA to lead the agency’s food division in February 2025 after working as a corporate lawyer at Jones Day and Baker Donelson. He does not have a medical degree, typically a credential expected for FDA leaders.

Impact on General Dentistry

Dental products are regulated through FDA’s device center, meaning the shift in leadership may introduce near-term regulatory uncertainty and possible delays in device oversight and approval. However, given that Acting Commissioner Diamantas’ experience is heavily concentrated in food policy, it is unlikely that day-to-day dental regulations will be heavily impacted.